A cohort study of antihypertensive treatments and risk of renal cell cancer
Why the study?
Does antihypertensive treatment increase the risk of renal cell carcinoma in the general population?
Population
335,682 county residents in North Jutland County, Denmark (1989-2002)
Comparison
Antihypertensive treatment (AHT) vs Nonusers in the general population, and users of…
Design
Cohort
Follow-up
average 10 years (range 0-13)
Authors
Discussion
Loading...
Member takes
Implication
No AHT changes warranted for RCC risk; confirms confounding by indication in observational data.
Structured PICO
Does antihypertensive treatment increase the risk of renal cell carcinoma in the general population?
P
Population
335,682 county residents in North Jutland County, Denmark (1989-2002)
I
Intervention
Antihypertensive treatment (AHT)
C
Comparator
Nonusers in the general population, and users of beta blockers (internal reference)
O
Outcome
Risk of renal cell carcinoma (RCC)safety
The apparent increased risk of renal cell carcinoma among users of antihypertensive treatments is likely due to confounding by indication and protopathic bias rather than a true causal relationship.
Limitations
- confounding due to failure to control for pre-existing hypertension
- protopathic bias
Cite This Study
Fryzek et al. (2005) studied this question.